CalciMedica (NASDAQ:CALC – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect CalciMedica to post earnings of ($0.48) per share for the quarter.
CalciMedica Stock Down 1.4 %
NASDAQ:CALC opened at $2.05 on Wednesday. CalciMedica has a 12-month low of $1.83 and a 12-month high of $6.27. The stock’s fifty day simple moving average is $2.45 and its 200-day simple moving average is $3.20. The firm has a market capitalization of $27.64 million, a P/E ratio of -1.90 and a beta of 1.20.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of CalciMedica in a research report on Tuesday, March 4th.
CalciMedica Company Profile
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Featured Stories
- Five stocks we like better than CalciMedica
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
